R. Herbst

Paul Baas, Ignacio I. Wistuba, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The proteasome inhibitor PS-341 in cancer therapy.

R. Herbst, B. Teicher, J. Adams, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

J. Fujimoto, I. Wistuba, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of epidermal growth factor receptor biology.

Roy S Herbst, R. Herbst, 2004, International journal of radiation oncology, biology, physics.

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Michael Peyton, John D. Minna, Li Shen, 2012, Clinical Cancer Research.

Phase I Trials Today

R. Herbst, P. LoRusso, D. Morgensztern, 2015 .

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Michael Peyton, John D. Minna, Lixia Diao, 2013, Clinical Cancer Research.

Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

R. Herbst, 2006, Clinical lung cancer.

Chemotherapy for advanced non-small cell lung cancer.

R. Herbst, N. Dang, A. Skarin, 1997, Hematology/oncology clinics of North America.

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

C. Bucana, R. Herbst, J. Wood, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo

Michael Peyton, John D. Minna, B. Nebiyou Bekele, 2010, PloS one.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Y. Shentu, R. Herbst, M. Ahn, 2016, The Lancet.

Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling

Connie Y. C. Ma, R. Herbst, Cheng-Pang Hsu, 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

R. Herbst, R. Kurzrock, A. Jubb, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma.

R. Herbst, P. O'dwyer, G. Lieberman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

R. Herbst, R. Kurzrock, W. Novotny, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer

R. Herbst, D. Camidge, M. Gordon, 2007 .

First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors

R. Herbst, E. Heath, P. LoRusso, 2007 .

Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors

R. Herbst, D. Branstetter, G. Eckhardt, 2007 .

Novel therapeutics for head and neck cancer

Edward S. Kim, R. Herbst, M. Kies, 2002, Current opinion in oncology.

Angiogenesis and lung cancer: potential for therapy.

R. Herbst, I. Fidler, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting vascular endothelial growth factor in patients with squamous cell lung cancer.

R. Herbst, D. Morgensztern, J. Boyer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.

P. Jänne, Bruce E. Johnson, D. Sugarbaker, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

L. Schwartz, R. Govindan, J. Neal, 2018, Journal of Immunotherapy for Cancer.

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

R. Herbst, D. Rimm, S. Gettinger, 2020, Clinical Cancer Research.

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

R. Herbst, S. Gettinger, J. Soria, 2013 .

Handbook of Advanced Cancer Care: Head and neck cancer

R. Herbst, M. Kies, 2003 .

Epidermal growth factor receptor biology (IMC-C225)

Edward S. Kim, F. Khuri, R. Herbst, 2001, Current opinion in oncology.

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

R. Herbst, D. Branstetter, S. Eckhardt, 2011, British Journal of Cancer.

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.

G. Giaccone, R. Herbst, E. Felip, 2021, Journal of Thoracic Oncology.

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

L. Schwartz, R. Herbst, F. Hirsch, 2021, JAMA oncology.

Frontline immunotherapy for NSCLC — the tale of the tail

R. Herbst, A. Chiang, 2020, Nature Reviews Clinical Oncology.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

R. Herbst, C. Fuchs, L. Paz-Ares, 2019, The Lancet. Oncology.

Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer?

R. Herbst, S. Goldberg, 2018, Cancer.

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

T. Dang, R. Herbst, D. Carbone, 2010, Lung cancer.

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

R. Herbst, J. Vermorken, N. Amellal, 2008, Cancer.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

R. Herbst, D. Ferry, R. Walgren, 2018, The oncologist.

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

F. Khuri, W. Hong, R. Herbst, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program.

I. Wistuba, J. Lee, R. Herbst, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).

K. Coombes, J. Lee, W. Hong, 2013 .

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

A. Vortmeyer, R. Herbst, A. Chiang, 2016, The Lancet. Oncology.

Mode of action of docetaxel - a basis for combination with novel anticancer agents.

Roy S Herbst, Fadlo R Khuri, F. Khuri, 2003, Cancer treatment reviews.

Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection

S. Farhadian, H. Krumholz, R. Herbst, 2020, medRxiv.

Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.

R. Herbst, D. Nguyen, Zongzhi Z. Liu, 2017, Cancer research.

Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin

Y. Maehara, R. Herbst, B. Teicher, 1997, International journal of cancer.

Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.

R. Herbst, B. Teicher, S. Keyes, 1997, In vivo.

PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

R. Herbst, K. Schalper, H. Kluger, 2020, Clinical Cancer Research.

Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis.

J. Koo, B. Ma, R. Herbst, 2015, Cancer research.

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

F. Khuri, W. Hong, R. Herbst, 2001, Lung cancer.

Integration of Molecular Profiling into the Lung Cancer Clinic

M. Ladanyi, A. Iafrate, M. Kris, 2009, Clinical Cancer Research.

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Roy S Herbst, Diane D. Liu, Diane D Liu, 2007, Clinical Cancer Research.

Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Diane D. Liu, W. Hong, I. Wistuba, 2014, Clinical lung cancer.

EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.

M. Ladanyi, M. Kris, W. Pao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly

A. Rossi, C. Gridelli, R. Herbst, 2004, Cancer.

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer

R. Herbst, D. Rimm, S. Langermann, 2022, Laboratory Investigation.

The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.

M. Chernick, R. Herbst, C. Presant, 2012, Cancer research.

Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials

C. Gotay, R. Herbst, K. Kelly, 2007 .

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

Tae Kon Kim, R. Herbst, Lieping Chen, 2022, Nature Reviews Drug Discovery.

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

R. Herbst, J. Heymach, A. Ryan, 2007, Expert opinion on investigational drugs.

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.

R. Herbst, C. Ng, R. Kurzrock, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer.

R. Herbst, E. Rasmussen, L. Paz-Ares, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma.

R. Herbst, E. Waxman, 2002, Seminars in oncology nursing.

Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.

R. Herbst, J. Abbruzzese, Marlene Z. Cohen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

ADAURA: Phase III, Double‐blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation‐positive Early‐stage NSCLC After Complete Surgical Resection

M. Tsuboi, R. Herbst, Yi-long Wu, 2018, Clinical lung cancer.

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Mark M. Davis, P. A. Futreal, R. Emerson, 2020, Nature Communications.

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

R. Herbst, R. Kurzrock, H. Burris, 2011, Cancer Chemotherapy and Pharmacology.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

R. Herbst, J. Heymach, F. D. De Braud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of an Immunohistochemical Assay for Siglec-15

R. Herbst, D. Rimm, S. Langermann, 2022, Laboratory Investigation.

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

A. Madabhushi, M. Mino‐Kenudson, R. Herbst, 2022, Journal for ImmunoTherapy of Cancer.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

L. Schwartz, R. Govindan, J. Neal, 2022, Journal for ImmunoTherapy of Cancer.

Erlotinib (Tarceva): an update on the clinical trial program.

R. Herbst, 2003, Seminars in oncology.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.

I. Pastan, C. Bucana, R. Herbst, 2002, Molecular cancer therapeutics.

Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer

R. Herbst, K. Shibuya, D. Morgensztern, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

2007 Highlights from: the 12th World Conference on Lung Cancer Seoul, South Korea; September 2-6, 2007

R. Herbst, D. Gandara, C. Langer, 2007 .

Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)".

S. Lippman, J. Roth, S. Swisher, 2008, Chest.

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

R. Herbst, R. Kurzrock, D. Camidge, 2010, Clinical Cancer Research.

A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC)

D. Sugarbaker, R. Herbst, N. Choi, 2000 .

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

R. Govindan, R. Herbst, K. Kelly, 2006, Lung cancer.

Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer

R. Herbst, A. Sandler, David H. Johnson, 2004, Clinical Cancer Research.

Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy

Edward S. Kim, S. Lippman, F. Khuri, 2009, American journal of clinical oncology.

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.

R. Herbst, F. Fossella, G. Blumenschein, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Diane D. Liu, J. Lee, R. Herbst, 2003, Lung cancer.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

R. Herbst, D. Carbone, S. Solomon, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

M. Kris, G. Demetri, R. Herbst, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members.

K. Cummings, N. Hanna, R. Herbst, 2013, Journal of oncology practice.

Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients

K. Cummings, R. Herbst, A. Hutson, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer

R. Herbst, D. Rimm, K. Schalper, 2015, Journal of Immunotherapy for Cancer.

Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology

R. Herbst, D. Gandara, P. Lara, 2009 .

Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009

R. Herbst, D. Gandara, P. Lara, 2009 .

Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.

R. Herbst, 2008, Clinical lung cancer.

Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?

R. Herbst, 2008, Clinical lung cancer.

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

R. Herbst, J. Heymach, J. Hou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A step towards treating KRAS-mutant NSCLC.

R. Herbst, J. Schlessinger, J. Boyer, 2013, The Lancet. Oncology.

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

R. Herbst, J. Heymach, A. Ryan, 2008 .

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.

David R. Jones, M. Tsuboi, R. Herbst, 2021, The Journal of thoracic and cardiovascular surgery.

Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

R. Herbst, A. Sandler, 2006, Clinical Cancer Research.

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.

Diane D. Liu, J. Lee, R. Herbst, 2006, Clinical lung cancer.

What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?

R. Herbst, A. Onn, 2005, Nature Clinical Practice Oncology.

Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety

P. Thall, F. Khuri, W. Hong, 2000 .

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE.

M. Kris, R. Herbst, V. Miller, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.

Joe Y. Chang, T. Guerrero, R. Herbst, 2007, International journal of radiation oncology, biology, physics.

Treatment of Advanced Non-Small Cell Lung Cancer in 2018.

R. Herbst, D. Doroshow, 2018, JAMA oncology.

Angiogenesis inhibition in the treatment of lung cancer.

R. Herbst, E. Vokes, A. Sandler, 2006, Clinical advances in hematology & oncology : H&O.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

L. Sequist, R. Herbst, S. Gettinger, 2018, European journal of cancer.

Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008

R. Herbst, D. Gandara, P. Lara, 2008 .

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

David M Jablons, Eric Holmgren, Roy S Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models

R. Herbst, B. Teicher, H. Takeuchi, 1998, Cancer Chemotherapy and Pharmacology.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

C. Obasaju, G. Scagliotti, R. Herbst, 2010, Clinical lung cancer.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

William Pao, Marc Ladanyi, Vincent A. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

ゲフィチニブ（イレッサ®）の非盲検多施設国際共同による長期継続投与試験

R. Herbst, M. Ranson, 和彦中川, 2006 .

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.

M. Kris, D. Cella, R. Herbst, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials

G. Giaccone, M. Kris, D. Haber, 2005 .

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

Benjamin M Yeh, Frederick Kelcz, Roy S Herbst, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted drug delivery strategies to treat lung metastasis

Roy S Herbst, R. Herbst, A. Onn, 2009, Expert opinion on drug delivery.

Introduction by the Guest Editors.

Sarah B Goldberg, Roy S Herbst, R. Herbst, 2020, Cancer journal.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

G. Giaccone, N. Reinmuth, R. Herbst, 2020, The New England journal of medicine.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Xin Li, Roy S Herbst, Hai T Tran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).

R. Herbst, V. Papadimitrakopoulou, H. Tran, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel Agents in the Treatment of Lung Cancer

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical Cancer Research.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

John V Heymach, Kevin R Coombes, Lixia Diao, 2012, Journal of the National Cancer Institute.

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

Roy S Herbst, R. Herbst, C. Langer, 2002, Seminars in oncology.

Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.

Ara A Vaporciyan, Roy S Herbst, Edith M Marom, 2005, Radiology.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Guoping Cai, David L Rimm, Soldano Ferrone, 2017, Cancer discovery.

Clinical Features and Management of Acquired Resistance to PD‐1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer

R. Herbst, A. Chiang, D. Zelterman, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

John V Heymach, Young-Ho Ahn, Roy S Herbst, 2013, Cancer research.

Monoclonal antibodies to target epidermal growth factor receptor–positive tumors

Roy S Herbst, R. Herbst, D. Shin, 2002, Cancer.

Dermatologic side effects associated with gefitinib therapy: clinical experience and management.

R. Herbst, P. LoRusso, Michele Purdom, 2003, Clinical lung cancer.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

R. Herbst, P. Elvin, A. Platt, 2015, BMC Cancer.

Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

Edward S. Kim, S. Lippman, W. Hong, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Roy S Herbst, W. Hong, J. Baselga, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

A. Harris, J. Baselga, R. Herbst, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lung-MAP--framework, overview, and design principles.

Mary W Redman, Roy S Herbst, R. Herbst, 2015, Chinese clinical oncology.

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

David Wholley, Jeffrey D Bradley, Dana Sparks, 2015, Clinical Cancer Research.

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

R. Herbst, K. Kelly, D. Gandara, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer

Stacey, L. Schwartz, M. Leblanc, 2021 .

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

L. Schwartz, R. Herbst, F. Hirsch, 2021, Journal for ImmunoTherapy of Cancer.

Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

R. Herbst, K. Kelly, D. Gandara, 2020 .

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treated PI 3 K-Positive Patients with Stage IV Squamous Cell Lung Cancer ( Lung-MAP Sub-Study )

Jeffrey, Crawford, R. Herbst, 2019 .

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

R. Price, J. Minna, Jie Zhang, 2005, Cancer research.

Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy.

G. Giaccone, R. Herbst, L. Bailey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer.

A. Abernethy, C. Gross, R. Herbst, 2019, Journal of geriatric oncology.

Lung cancer in patients under age 40.

D. Sugarbaker, R. Herbst, A. Skarin, 2001, Lung cancer.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

I. Wistuba, J. Lee, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging therapies in non-small-cell lung cancer.

F. Khuri, R. Herbst, F. Fossella, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.

R. Herbst, B. Teicher, S. Keyes, 1997, In vivo.

Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment

G. Giaccone, R. Herbst, L. Bailey, 2004 .

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Thoracic Oncology.

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

M. Socinski, R. Govindan, Kwok-Kin Wong, 2007, Clinical Cancer Research.

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.

I. Wistuba, J. Lee, R. Herbst, 2020, Clinical radiology.

The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.

Edward S. Kim, W. Hong, I. Wistuba, 2014 .

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.

R. Herbst, M. Redman, S. Gettinger, 2022, JAMA oncology.

Small molecule combats cancer-causing KRAS protein at last

R. Herbst, J. Schlessinger, 2019, Nature.

Positive and negative regulatory elements in the mouse albumin enhancer.

J. Darnell, R. Herbst, L. Babiss, 1989, Proceedings of the National Academy of Sciences of the United States of America.

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

R. Herbst, P. LoRusso, R. Kurzrock, 2010, Clinical Cancer Research.

RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.

L. Tanoue, R. Herbst, K. Schalper, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.

R. Herbst, 2003, Seminars in oncology.

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

R. Herbst, M. Carducci, C. Britten, 2006, Clinical Cancer Research.

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

M. Socinski, R. Herbst, F. Hirsch, 2018 .

MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

M. Socinski, R. Herbst, F. Hirsch, 2017 .

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.

Tae Kon Kim, R. Herbst, K. Schalper, 2021, Cancer discovery.

Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer.

Edward S. Kim, R. Herbst, M. Truong, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study.

R. Herbst, P. Fidias, J. Heymach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

R. Herbst, D. Prager, I. Dimery, 2005 .

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

R. Herbst, J. Heymach, D. Prager, 2005 .

ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer

R. Herbst, R. Langley, A. Onn, 2004 .

Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer

R. Herbst, R. Komaki, A. Ryan, 2005 .

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results.

R. Herbst, J. Heymach, D. Prager, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib

M. Kris, R. Herbst, M. Fukuoka, 2003 .

Phase I participants’ views of quality of life and trial participation burdens

R. Herbst, J. Abbruzzese, Marlene Z. Cohen, 2007, Supportive Care in Cancer.

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)

Edward S. Kim, J. Weinstein, K. Coombes, 2011 .

Enzastaurin , a Protein Kinase C B ^ Selective Inhibitor , and Its PotentialApplicationasanAnticancer AgentinLungCancer

R. Herbst, Y. Oh, A. Wagle, 2007 .

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

R. Herbst, L. Paz-Ares, M. Reck, 2022, Journal for ImmunoTherapy of Cancer.

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

Robert E. Brown, R. Herbst, R. Kurzrock, 2012, Molecular Cancer Therapeutics.

Spotlight on Clinical Response Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo 2 L / TRAIL ( Dulanermin ) , a Dual Proapoptotic Receptor ( DR 4 / DR 5 ) Agonist

Robert E. Brown, R. Herbst, R. Kurzrock, 2012 .

P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC: Topic: IT

R. Herbst, A. Chiang, D. Zelterman, 2017 .

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

M. Tsuboi, Jie He, R. Herbst, 2020, The New England journal of medicine.

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342

Edward S. Kim, R. Herbst, K. Kelly, 2007 .

The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein

J. Darnell, E. Boczko, R. Herbst, 1990, Molecular and cellular biology.

Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors

R. Herbst, E. Jackson, R. Kurzrock, 2005 .

151 AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors

R. Herbst, C. Ng, R. Kurzrock, 2004 .

977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

Edward S. Kim, W. Hong, R. Herbst, 2003 .

Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.

R. Herbst, B. Teicher, D. Buxton, 1998, Anticancer research.

When immunotherapy meets surgery in non-small cell lung cancer.

R. Herbst, Lieping Chen, Meina Wang, 2022, Cancer cell.

Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.

L. Sequist, R. Herbst, S. Gettinger, 2015 .

Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor.

A. Jimeno, R. Herbst, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types.

J. Darnell, R. Herbst, L. Babiss, 1987, Genes & development.

Imaging in drug development.

R. Herbst, 2004, Clinical advances in hematology & oncology : H&O.

The changing face of Phase 1 cancer clinical trials

S. Lippman, R. Herbst, R. Kurzrock, 2009, Cancer.

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.

J. Minna, G. Scagliotti, R. Govindan, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Hong Wang, R. Herbst, L. Paz-Ares, 2021 .

The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53 -Driven Lung Cancer

J. Koo, R. Herbst, A. Iwasaki, 2019 .

Diminished but not dead: chemotherapy for the treatment of NSCLC.

R. Herbst, M. Sznol, 2016, The Lancet. Oncology.

R. Herbst, M. Ahn, E. Felip, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial

R. Herbst, P. Fidias, J. Heymach, 2005 .

90PDPreviously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

R. Herbst, L. Paz-Ares, J. Bendell, 2017 .

A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.

R. Herbst, D. Petrylak, D. Ferry, 2017 .

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).

R. Herbst, C. Fuchs, J. Bendell, 2017 .

Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.

W. Hong, I. Wistuba, R. Herbst, 2010 .

[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.

K. Forster, J. Roth, R. Herbst, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor.

R. Herbst, S. Sone, S. Yano, 2003, Methods in molecular medicine.

A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

Upendra, Chiang, A. Vortmeyer, 2017 .

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Edward F. Jackson, Kenneth Hess, James L. Abbruzzese, 2004, Investigational New Drugs.

The KRAS-variant and treatment response in BATTLE-1.

Edward S. Kim, F. Slack, Jun Yu, 2014 .

O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy

T. Dang, R. Herbst, V. Miller, 2005 .

Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors.

R. Herbst, H. Rugo, G. Wilding, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancer.

R. Herbst, R. Lilenbaum, 2000, Clinical lung cancer.

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

J. Baselga, R. Herbst, J. Tabernero, 2010 .

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer

R. Herbst, D. Rimm, S. Langermann, 2022, Laboratory Investigation.

Prostate carcinoma response to cytotoxic therapy: in vivo resistance.

Y. Kakeji, R. Herbst, B. Teicher, 1997, In vivo.

BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis

R. Herbst, D. Rimm, S. Gettinger, 2019 .

Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study.

R. Herbst, R. Kurzrock, L. Rosen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors

R. Herbst, G. Wilding, H. Rugo, 2004 .

Acute in vivo resistance in high-dose therapy.

R. Herbst, B. Teicher, S. Keyes, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

R. Herbst, S. Dakhil, D. Camidge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

R. Herbst, J. Bradley, K. Kelly, 2017 .

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

R. Herbst, J. Bradley, K. Kelly, 2017 .

A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.

R. Herbst, K. Kelly, D. Gandara, 2017 .

Methodological and practical challenges for personalized cancer therapies

Juri G. Gelovani, Ignacio I. Wistuba, Roy S. Herbst, 2011, Nature Reviews Clinical Oncology.

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

P. Ascierto, J. Larkin, M. Atkins, 2022, Journal for ImmunoTherapy of Cancer.

Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology.

K. Viswanath, R. Herbst, A. Alberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TheMouseAlbumin Enhancer Contains aNegative Regulatory Element ThatInteracts withaNovelDNA-Binding Protein

R. Herbst, L. Babiss, 1990 .

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

A. Jimeno, R. Herbst, R. Kurzrock, 2010 .

Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): A phase I trial for patients with stage III non-small cell lung cancer (NSCLC)

F. Khuri, W. Hong, R. Herbst, 2000 .

Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342.

J. Crowley, R. Herbst, K. Kelly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of Thoracic Oncology.

Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study.

R. Herbst, J. Bendell, D. Ferry, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.

A. Abernethy, C. Gross, R. Herbst, 2017 .

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

J. Lunceford, M. Ayers, R. Herbst, 2019 .

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials

D. Berry, R. Herbst, E. Rubin, 2012, Clinical Cancer Research.

Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer

Diane D. Liu, F. Khuri, W. Hong, 2000 .

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

R. Herbst, A. Ryan, H. Mann, 2009, Clinical Cancer Research.

Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)

Parth D. Shah, D. Patrick, R. Herbst, 2021, JCO oncology practice.

Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.

R. Herbst, A. Chiang, S. Gettinger, 2018 .

Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.

I. Wistuba, J. Lee, J. Welsh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Jing Wang, I. Wistuba, W. Lu, 2015, Clinical Cancer Research.

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer

R. Herbst, S. Goldberg, B. Henick, 2014, Expert opinion on therapeutic targets.

Tyrosine hydroxylase-immunoreactive neurons of the hypothalamus: A light and electron microscopic study

J. Powell, R. Herbst, A. Pol, 1984, Neuroscience.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Michael Peyton, Humam Kadara, Murim Choi, 2015, Cancer discovery.

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting

A. Abernethy, C. Gross, R. Herbst, 2018, JAMA.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Edward S. Kim, Diane D. Liu, W. Hong, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection

S. Farhadian, H. Krumholz, R. Herbst, 2021, PloS one.

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

R. Herbst, C. Stevens, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Lisofylline as a modifier of radiation therapy.

C. Coleman, R. Herbst, B. Teicher, 1996, Oncology research.

An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

R. Herbst, Dennie V. Jones, A. Sandler, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Xu Zhou, R. Herbst, D. Rimm, 2019, Nature Medicine.

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

R. Herbst, S. Goldberg, M. Grant, 2021, Nature Reviews Clinical Oncology.

The role of growth factor signaling in malignancy.

R. Herbst, J. Mendelsohn, A. Onn, 2003, Cancer treatment and research.

Regulation of adenovirus and cellular gene expression and of cellular transformation by the E1B-encoded 175-amino-acid protein

P. Fisher, R. Herbst, L. Babiss, 1988, Journal of virology.

Small-cell lung cancer: prognostic factors and changing treatment over 15 years.

R. Herbst, L. Gaspar, J. Crawford, 2012, Clinical lung cancer.

Multitargeted inhibitors in lung cancer: new clinical data.

R. Herbst, A. Onn, J. Bar, 2008, Clinical lung cancer.

Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

R. Herbst, D. Rimm, K. Politi, 2019, Clinical Cancer Research.

The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function

E. Boczko, R. Herbst, L. Babiss, 1990, Journal of virology.

New targets for the treatment of advanced non-small cell lung cancer.

Edward S. Kim, F. Khuri, R. Herbst, 2002, Cancer chemotherapy and biological response modifiers.

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

A. D. Van den Abbeele, T. Dang, R. Herbst, 2007, Clinical Cancer Research.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

R. Herbst, B. Sabloff, K. Pisters, 2004, Lung cancer.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

David Cella, Karen Kelly, Roy S Herbst, 2003, JAMA.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Patricia L. Harris, G. Giaccone, M. Kris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current management of advanced non-small cell lung cancer: targeted therapy.

R. Herbst, A. Onn, T. Isobe, 2005, Seminars in oncology.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

D. Yankelevitz, I. Wistuba, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).

R. Herbst, K. Kelly, D. Gandara, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Title Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Simion I. Chiosea, R. Herbst, Lin Wang, 2015 .

Toward personalized treatment approaches for non-small-cell lung cancer

C. Boshoff, R. Herbst, Meina Wang, 2021, Nature Medicine.

5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.

R. Herbst, S. Novello, P. Baas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).

R. Herbst, K. Kelly, D. Gandara, 2020, Clinical lung cancer.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Immunotherapy for Cancer.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

V. Gebski, R. Herbst, T. Mok, 2017, JAMA oncology.

4-18-2017 The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31 st anniversary annual meeting Howard

M. Atkins, R. Herbst, L. Garrison, 2018 .

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting

M. Atkins, R. Herbst, L. Garrison, 2017, Journal of Immunotherapy for Cancer.

Immunotherapy in Lung Cancer.

R. Herbst, D. Morgensztern, L. Du, 2017, Hematology/oncology clinics of North America.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

R. Herbst, D. Rimm, K. Schalper, 2016, Clinical Cancer Research.

Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer

R. Herbst, D. Morgensztern, 2016, Clinical Cancer Research.

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research

R. Herbst, K. Schalper, E. Kaftan, 2016, Clinical Cancer Research.

Gefitinib — a novel targeted approach to treating cancer

Masahiro Fukuoka, Roy S. Herbst, J. Baselga, 2004, Nature Reviews Cancer.

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition

R. Herbst, Ho-Yyoung Lee, S. Oh, 2006, Molecular Cancer Therapeutics.

inhibition independent urokinase-type plasminogen activator − factor protein-3 in lung cancer is mediated by insulin-like growth Antimetastatic activity of insulin-like growth factor binding

R. Herbst, Ho-Yyoung Lee, S. Oh, 2006 .

Angiogenesis, metastasis, and lung cancer. An overview.

R. Herbst, A. Onn, 2003, Methods in molecular medicine.

Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial

J Jack Lee, Edward S. Kim, Ignacio Wistuba, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ZD1839 (Iressa) in non-small cell lung cancer.

R. Herbst, M. Kies, 2001, The oncologist.

ZD1839 (Iressa TM ) In Non-Small-Cell Lung Cancer

F. Khuri, R. Herbst, K. Pisters, 2001 .

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

Ryan D. Chow, R. Herbst, Xiaoyu Zhou, 2019, Cell.

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD 8 T Cells Graphical

Ryan D. Chow, R. Herbst, Xiaoyu Zhou, 2019 .

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

R. Herbst, Jeri Kim, R. Zinner, 2002, Lung cancer.

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

J. Koo, R. Herbst, A. Iwasaki, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

James X. Sun, Jing Wang, J. Minna, 2018, Oncotarget.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket

L. Schwartz, R. Yelensky, M. Leblanc, 2015 .

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

R. Herbst, J. Eder, J. Jürgensmeier, 2014, Clinical Cancer Research.

Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

Roy S Herbst, Waun K Hong, Arlene M Correa, 2004, Clinical Cancer Research.

EGFR tyrosine kinase inhibitors in squamous cell lung cancer.

R. Herbst, F. Hirsch, D. Gandara, 2015, The Lancet. Oncology.

DRAFT FOR PUBLIC COMMENT Defining Clinically Meaningful Outcomes: ASCO Recommendations to Raise the Bar for Clinical Trials

L. Ellis, C. Sima, D. Sargent, 2013 .

Microenvironment and Immunology CXCR 2 Expression inTumorCells Is aPoorPrognosticFactor and Promotes Invasion and Metastasis in Lung Adenocarcinoma

Edward S. Kim, Diane D. Liu, S. Lippman, 2013 .

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Abhijit A. Patel, S. Mane, N. Carriero, 2018, Clinical Cancer Research.

Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.

C. Bucana, F. Khuri, W. Hong, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Angiogenesis as a target for cancer therapy.

R. Herbst, K. Kaban, 2002, Hematology/oncology clinics of North America.

Antiangiogenic Cancer Therapy

R. Herbst, J. Abbruzzese, D. Davis, 2007 .

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

A. Bleyer, H. Choy, J. Lee, 2010, Journal of the National Cancer Institute.

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Eric Song, Elizabeth B White, Patrick Wong, 2020, Nature.

Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial

Edward S. Kim, Jing Wang, J. Minna, 2013 .

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

R. Herbst, S. Gettinger, R. Homer, 2013, Cancer cytopathology.

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

L. Schwartz, M. Leblanc, R. Herbst, 2020, The Lancet. Oncology.

OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

J. Neal, R. Herbst, F. Hirsch, 2021 .

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Checkpoint Inhibition in Lung Cancer

R. Herbst, D. Morgensztern, 2018 .

Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice

R. Herbst, I. Fidler, R. Langley, 2007, Molecular Cancer Therapeutics.

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

R. Herbst, H. Rugo, G. Wilding, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

R. Herbst, A. Sandler, 2008, The oncologist.

Use of novel second-line targeted therapies in non-small cell lung cancer.

R. Herbst, E. Massarelli, 2006, Seminars in oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Y. Kluger, R. Herbst, A. Chiang, 2020, The Lancet. Oncology.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Roy S Herbst, Vincent Miller, Rafael Rosell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

G. Giaccone, G. Scagliotti, R. Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2020, Clinical lung cancer.

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Edward S. Kim, Diane D. Liu, Jing Wang, 2017, Science Translational Medicine.

Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.

K. Ang, R. Herbst, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

N. Hanna, J. Baselga, R. Herbst, 2013, European journal of cancer.

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Razelle Kurzrock, David S. Hong, Antonio Jimeno, 2012, Clinical Cancer Research.

Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells.

J. Darnell, R. Herbst, F. Sladek, 1991, The New biologist.

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

R. Herbst, Lieping Chen, Esten N Vandsemb, 2022, Nature Reviews Drug Discovery.

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

R. Herbst, N. Vasan, J. Boyer, 2014, Clinical Cancer Research.

Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

L. Bierut, S. David, A. Hyland, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement

R. Herbst, B. Toll, T. Brandon, 2013, Clinical Cancer Research.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015, Journal of the National Cancer Institute.

Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.

J. Taube, M. Oberley, R. Herbst, 2022, JCO precision oncology.

Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.

R. Herbst, F. Shepherd, E. Felip, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

R. Herbst, F. Hirsch, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

G. Bepler, R. Herbst, Y. Oh, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Li Shen, John V Heymach, Kevin R Coombes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

R. Herbst, D. Rimm, S. Gettinger, 2019, Clinical Cancer Research.

Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer

G. Gladish, R. Munden, R. Herbst, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

R. Herbst, L. Hart, D. Ramies, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiogenesis inhibitors in lung cancer

Edward S. Kim, R. Herbst, 2002, Current oncology reports.

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

M. Tsuboi, R. Herbst, Yi-long Wu, 2020 .

A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung

R. Herbst, Z. Shun, V. Miller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

J. Baselga, R. Nicholson, R. Herbst, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protein Kinase C Inhibitors in the Treatment of Non–Small Cell Lung Cancer

R. Herbst, Y. Oh, M. Lahn, 2007 .

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

P. Thall, F. Khuri, R. Herbst, 2001, Cancer.

Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.

R. Herbst, J. Tseng, A. Onn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immuno-thermal ablations – boosting the anticancer immune response

R. Herbst, S. Gettinger, J. Ludwig, 2017, Journal of Immunotherapy for Cancer.

Surrogate markers in antiangiogenesis clinical trials

R. Herbst, D. McConkey, J. Abbruzzese, 2003, British Journal of Cancer.

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

L. Ellis, C. Bucana, R. Herbst, 2000, The American journal of pathology.

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

B. Kramer, M. Kris, R. Schilsky, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.

D. Hanahan, S. Libutti, R. Herbst, 2004, Journal of immunotherapy.

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.

L. Ellis, K. Hess, C. Bucana, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)

R. Herbst, V. Miller, L. Hart, 2007 .

Antiangiogenic tumor therapy.

Wei Zhang, R. Herbst, D. McConkey, 2003, BioTechniques.

Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

R. Herbst, A. Sandler, 2004, Clinical lung cancer.

BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC

R. Herbst, S. Kim, 2022, Nature reviews. Clinical oncology.

Therapeutic options to target angiogenesis in human malignancies

R. Herbst, 2006, Expert opinion on emerging drugs.

Angiogenesis pathway inhibitors.

R. Herbst, H. Hurwitz, T. Isobe, 2005, Cancer chemotherapy and biological response modifiers.

Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

R. Herbst, A. Sandler, 2004, The oncologist.

Targeted Therapy in Solid Tumors: Lung Cancer

R. Herbst, D. Morgensztern, S. Waqar, 2015 .

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Edward S. Kim, C. Obasaju, G. Gladish, 2005, Cancer.

Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.

R. Herbst, T. Lynch, A. Sandler, 2009, Clinical lung cancer.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

R. Herbst, E. Rasmussen, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

R. Herbst, V. Papadimitrakopoulou, G. Blumenschein, 2006, Clinical Cancer Research.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

J. Hainsworth, R. Herbst, L. Hart, 2011, The Lancet.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

R. Herbst, Ju-Seog Lee, F. Ciardiello, 2011, The Journal of clinical investigation.

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

R. Herbst, R. Komaki, I. Fidler, 2007, Molecular Cancer Therapeutics.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Jing Wang, I. Wistuba, R. Herbst, 2017, Clinical Cancer Research.

E2F8 as a Novel Therapeutic Target for Lung Cancer.

J. Koo, R. Herbst, J. Platt, 2015, Journal of the National Cancer Institute.

“Companion Diagnostics”: Has Their Time Come and Gone?

R. Herbst, F. Hirsch, P. Bunn, 2014, Clinical Cancer Research.

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

Diane D. Liu, F. Khuri, J. Lee, 2002, Cancer.

Integration of targeted therapies in gemcitabine chemotherapy regimens.

R. Herbst, G. Blumenschein, 2003, Clinical lung cancer.

Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.

R. Herbst, 2002, Clinical lung cancer.

Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents

R. Herbst, R. Lilenbaum, 2008 .

Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.

R. Herbst, R. Zinner, 2004, Clinical lung cancer.

Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development

R. Herbst, Caimiao Wei, V. Papadimitrakopoulou, 2014, Statistics in Biosciences.

Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.

L. Ellis, C. Bucana, R. Herbst, 2000, Cancer research.

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

A. Mansfield, R. Herbst, T. Mok, 2021, JTO clinical and research reports.

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

L. Schwartz, R. Herbst, F. Hirsch, 2021, Clinical Lung Cancer.

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

R. Herbst, S. Gettinger, K. Kelly, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.

R. Herbst, S. Novello, G. Ceresoli, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFRMutations in Non – Small-Cell Lung Cancer Find , Divide , and Conquer

R. Herbst, K. Politi, D. Morgensztern, 2015 .

Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis

I. Wistuba, R. Herbst, R. Komaki, 2012, Clinical Cancer Research.

Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts

Edward S. Kim, J. Weinstein, K. Coombes, 2012 .

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer

R. Herbst, A. Ryan, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Advanced Non-Small Cell Lung Cancer: Second-line Therapy With Novel Agents

R. Herbst, E. Massarelli, 2008 .

IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)

W. Hong, R. Herbst, W. Hong, 2009 .

Molecular origins of lung cancer: prospects for personalized prevention and therapy.

Kwok-Kin Wong, R. Herbst, D. Carbone, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Roy S Herbst, R. Herbst, K. Politi, 2015, JAMA oncology.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Jing Wang, J. Minna, S. Toyooka, 2017, Molecular Cancer Therapeutics.

1 JAK 1 / STAT 3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer

Jing Wang, J. Minna, S. Toyooka, 2017 .

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Elizabeth B White, M. C. Muenker, S. Farhadian, 2020, Nature.

Guillain-Barré syndrome following allogeneic bone marrow transplantation

P. Wen, R. Herbst, R. Soiffer, 1997, Neurology.

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

R. Herbst, M. Truong, F. Fossella, 2004, Cancer Chemotherapy and Pharmacology.

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

M. Kris, J. Baselga, R. Herbst, 2000 .

Angiogenesis inhibition and lung-cancer therapy.

R. Herbst, A. Onn, J. Bar, 2014, The Lancet Oncology.

Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study).

R. Herbst, D. Morgensztern, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress

W. Hong, J. Koo, R. Herbst, 2015, PloS one.

Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

K. Coombes, Jing Wang, J. Minna, 2011, Cancer research.

Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

J. Gu, F. Khuri, W. Hong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Miscellaneous agents.

R. Herbst, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune checkpoint therapy for non-small-cell lung cancer: an update.

R. Herbst, B. Xia, 2016, Immunotherapy.

Molecular events surrounding the angiogenic switch of lung cancer

R. Herbst, A. Onn, J. Bar, 2012 .

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.

Tae Kon Kim, R. Herbst, Lieping Chen, 2018, Trends in immunology.

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC).

R. Herbst, R. Hermann, L. Fehrenbacher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD1839 (Iressa) in non-small-cell lung cancer.

F. Khuri, R. Herbst, K. Pisters, 2002, Clinical lung cancer.

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

R. Herbst, M. Truong, M. Carducci, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic S tudies o f t he E pidermal G rowth F actor Receptor I nhibitor Z D1839 i n S kin F rom C ancer P atients: Histopathologic a nd M olecular C onsequences o f Receptor I nhibition

J. Baselga, R. Nicholson, R. Herbst, 2002 .

Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial

F. Khuri, R. Herbst, K. Pisters, 2001 .

Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Jennifer A. Hobin, K. Viswanath, N. Hanna, 2015, Clinical Cancer Research.

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research

M. Fiore, N. Rigotti, R. Herbst, 2016, Clinical Cancer Research.

Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop.

R. Herbst, S. Nass, B. Toll, 2014, The oncologist.

AACR Celebrates 50 Years of Tobacco Research and Policy

Jennifer A. Hobin, R. Herbst, E. Gritz, 2014, Clinical Cancer Research.

OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

M. Tsuboi, R. Herbst, Yi-long Wu, 2021 .

LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

M. Tsuboi, Jie He, R. Herbst, 2020 .

The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer

R. Herbst, S. Goldberg, 2023, The Lancet.

Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery

D. Boffa, R. Herbst, F. Detterbeck, 2017, JAMA oncology.

Surgery: Future directions in multimodality therapy for NSCLC

J. Roth, R. Herbst, A. Tsao, 2010, Nature Reviews Clinical Oncology.

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.

R. Herbst, F. Hirsch, K. Kelly, 2021, Clinical lung cancer.

Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.

K. Ang, C. Bucana, R. Herbst, 2007, International journal of radiation oncology, biology, physics.

Angiogenesis and lung cancer: prognostic and therapeutic implications.

R. Herbst, A. Onn, A. Sandler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tobacco and cancer: an American Association for Cancer Research policy statement.

K. Viswanath, R. Herbst, P. Shields, 2010, Cancer research.

Highlights from: The 13th world conference on lung cancer

R. Herbst, D. Gandara, P. Lara, 2009 .

To kill a tumor cell: the potential of proapoptotic receptor agonists.

R. Herbst, A. Ashkenazi, 2008, The Journal of clinical investigation.

Image Guidance of Screening, Staging and Combined Modality Management of Non–Small Cell Lung Cancer

J. Roth, R. Herbst, 2007 .

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

W. Curran, H. Choy, R. Herbst, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials.

K. Cummings, A. Hyland, R. Herbst, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of novel targeted therapies in the clinic

R. Herbst, Roy S. Herbst, 2005, British Journal of Cancer.

Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015 .

A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC

R. Herbst, P. Fidias, D. Prager, 2005 .

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction

R. Herbst, S. Gettinger, 2014, Cancer journal.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer

R. Herbst, K. Syrigos, K. Schalper, 2017, Clinical Cancer Research.

Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions

R. Herbst, N. Lindeman, D. Aisner, 2021, Frontiers in Medicine.

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer

J. Koo, R. Herbst, J. W. Lee, 2016, PloS one.

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

Edward S. Kim, R. Herbst, P. Harari, 2001, Seminars in oncology.

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

R. Herbst, P. Harari, E. Kim, 2002, Expert opinion on biological therapy.

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

R. Herbst, M. Carducci, C. Britten, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

R. Herbst, R. Cohen, J. de Castro Carpeno, 2012, British Journal of Cancer.

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

G. Giaccone, R. Herbst, M. Janas, 2009, Journal of Cancer Research and Clinical Oncology.

Molecular signatures of lung cancer--toward personalized therapy.

S. Lippman, R. Herbst, 2007, The New England journal of medicine.

Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

R. Herbst, N. Mullani, Yu Shen, 2004, Clinical Cancer Research.

Assessment of antiangiogenic effect using 99mTc-EC-endostatin.

David J. Yang, R. Herbst, D. Podoloff, 2002, Cancer biotherapy & radiopharmaceuticals.

Lung Endothelial MicroRNA‐1 Regulates Tumor Growth and Angiogenesis

M. Pisani, R. Herbst, J. Siegfried, 2017, American journal of respiratory and critical care medicine.

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

G. Demetri, R. Herbst, A. Rashid, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin

R. Herbst, J. Abbruzzese, H. Tran, 2001, Current oncology reports.

Treatment with HIF-1&agr; Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice

S. Lippman, R. Herbst, G. Powis, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation

P. Salovey, A. Latimer-Cheung, R. Herbst, 2014, Clinical Cancer Research.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Sanjiv J. Shah, M. Gladwin, G. Beck, 2017, American journal of respiratory and critical care medicine.

Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.

R. Herbst, D. Rimm, S. Gettinger, 2017 .

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

R. Herbst, K. Syrigos, D. Rimm, 2017, Clinical Cancer Research.

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

R. Herbst, 2002, Expert opinion on investigational drugs.

Targeting the epidermal growth factor receptor in non-small cell lung cancer.

R. Herbst, P. Bunn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting the epidermal growth factor receptor: prognostic and clinical implications

R. Herbst, 2003 .

Smoking cessation, version 1.2016 clinical practice guidelines in oncology

L. Bierut, S. David, A. Hyland, 2016 .

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

L. Zender, R. Herbst, C. Fuchs, 2020, Cancers.

A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.

R. Herbst, J. Bendell, D. Ferry, 2016 .

晚期非小细胞肺癌治疗策略的演变：从2009放眼2012

R. Herbst, D. Gandara, P. Mack, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.

R. Herbst, D. Gandara, P. Mack, 2009, Clinical lung cancer.

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Eugene A. Mash, Lei Du-Cuny, Emmanuelle J. Meuillet, 2010, Molecular Cancer Therapeutics.

Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.

R. Herbst, L. Gaspar, J. Crawford, 2005, Clinical lung cancer.

ZD1839 (IressaTM) in Non-Small Cell Lung Cancer

R. Herbst, 2002 .

Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients

Patrick Wong, Jon Klein, Benjamin Israelow, 2020, medRxiv.

Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow

Nizar A. Mullani, K. Lance Gould, Bruce J. Barron, 2008, Journal of Nuclear Medicine.

Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems?

R. Herbst, S. Baldassarri, L. Fucito, 2020, Cancer Prevention Research.

Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer Centers

R. Herbst, A. Alberg, B. Toll, 2014 .

Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

R. Herbst, Y. Oh, M. Lahn, 2007, Clinical Cancer Research.

Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.

K. Cummings, N. Hanna, R. Herbst, 2013 .

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

R. Herbst, L. Paz-Ares, J. Bendell, 2016 .

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

J. Lunceford, M. Ayers, R. Herbst, 2019, Annals of Oncology.

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.

W. Hong, R. Herbst, R. Komaki, 2009, International journal of radiation oncology, biology, physics.

Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Research (Excluding Clinical Trials).

Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography: A Comparison Study

R. Herbst, Y. Kodama, C. Ng, 2009, Journal of computer assisted tomography.

Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen

T. Dang, P. Massion, R. Herbst, 2009, Journal of Thoracic Oncology.

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.

R. Herbst, S. Ramalingam, P. Baas, 2014 .

Phase I study of recombinant human endostatin in patients with advanced solid tumors.

L. Ellis, K. Hess, W. Hong, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

R. Herbst, C. Fuchs, L. Paz-Ares, 2018 .

Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).

R. Herbst, C. Fuchs, D. Ferry, 2018 .

Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

R. Herbst, L. Paz-Ares, M. Sebastian, 2007 .

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

R. Govindan, R. Herbst, J. Schiller, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042

A. Mansfield, R. Herbst, T. Mok, 2019, Annals of Oncology.

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

W. Hong, R. Herbst, E. Vokes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression

G. Giaccone, R. Herbst, F. de Marinis, 2021, Frontiers in Oncology.

Larotrectinib in NTRK -Rearranged Solid Tumors

R. Herbst, F. H. Wilson, 2020 .

Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".

R. Herbst, F. H. Wilson, 2019, Biochemistry.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403).

R. Herbst, F. Hirsch, K. Kelly, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells

R. Herbst, M. Hung, Shih-Shin Chang, 2013, Clinical Cancer Research.

Opening Up to Precompetitive Collaboration

Sharyl J. Nass, Stephen H. Friend, Anna D. Barker, 2010, Science Translational Medicine.

Angiogenesis and lung cancer: implications for prognosis and treatment.

R. Herbst, A. Onn, 2007, The Lancet Oncology.

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

R. Herbst, R. Cohen, M. Tortorici, 2012, British Journal of Cancer.

Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)

R. Herbst, S. Frankel, 2004, Clinical Cancer Research.

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Edward S. Kim, J. Crowley, R. Herbst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of Thoracic Oncology.

Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)

Diane D. Liu, G. Gladish, S. Lippman, 2007 .

MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC)

D. D. Billheimer, T. Dang, R. Herbst, 2005 .

Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

R. Herbst, S. Novello, G. Ceresoli, 2018, Annals of Oncology.

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

G. Giaccone, N. Reinmuth, R. Herbst, 2019, Annals of Oncology.

Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.

A. Vortmeyer, R. Herbst, A. Chiang, 2015 .

KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536.

R. Herbst, F. Hirsch, D. Gandara, 2009, Journal of Clinical Oncology.

P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer

C. Bucana, W. Hong, R. Herbst, 2003 .

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel agents in the treatment of lung cancer: conference summary statement.

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

How to Promote and Organize Clinical Research in Lung Cancer

R. Herbst, J. Mazières, G. Zalcman, 2018 .

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists

R. Herbst, M. Rigney, L. Fenton, 2009 .

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}.

R. Herbst, R. Kurzrock, G. Weiss, 2010 .

Challenges and approaches to implementing master/basket trials in oncology.

J. Byrd, R. Schilsky, R. Herbst, 2019, Blood advances.

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

M. A. Ayers, R. Herbst, Yi-long Wu, 2021, Journal for ImmunoTherapy of Cancer.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway – Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

R. Herbst, J. Bradley, K. Kelly, 2019 .

Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors

L. Ellis, K. Hess, W. Hong, 2002 .

Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).

R. Herbst, D. Rimm, Joseph K. McLaughlin, 2014 .

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536

Edward S. Kim, R. Herbst, F. Hirsch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed in advanced NSCLC: a review of the clinical data.

R. Herbst, F. Fossella, R. Zinner, 2004, Oncology.

Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancer

H. Krumholz, R. Herbst, S. Aneja, 2021 .

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

R. Herbst, Y. Bang, J. Bono, 2014 .

83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A

R. Herbst, K. Kelly, D. Gandara, 2017 .

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.

R. Herbst, M. Ahn, E. Felip, 2017 .

G. Giaccone, R. Herbst, L. Bailey, 2004, Journal of Clinical Oncology.

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

R. Herbst, B. Teicher, R. Salgia, 2001, Cancer Chemotherapy and Pharmacology.

Angiogenesis inhibitors in clinical development for lung cancer.

M. Hidalgo, R. Herbst, S. Eckhardt, 2002, Seminars in oncology.

O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer

Edward S. Kim, W. Hong, R. Herbst, 2003 .

M. Tsuboi, R. Herbst, Yi-long Wu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials

C. Obasaju, G. Scagliotti, R. Herbst, 2008 .

Gefitinib: current and future status in cancer therapy.

R. Herbst, M. Kies, 2003, Clinical advances in hematology & oncology : H&O.

Master Protocol Multi-drug Registration Trial Design Proposal

R. Herbst, 2022 .

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

Edward S. Kim, R. Herbst, W. William, 2009, Nature Clinical Practice Oncology.

A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

F. Khuri, R. Herbst, J. Rigas, 2005 .

OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab

Y. Shentu, R. Herbst, H. Saka, 2017 .

MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)

R. Herbst, D. Zelterman, D. Rimm, 2017 .

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

Edward S. Kim, R. Herbst, V. Papadimitrakopoulou, 2011, Investigational New Drugs.

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer

Edward S. Kim, Diane D. Liu, R. Herbst, 2009, Cancer.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

G. Giaccone, N. Reinmuth, R. Herbst, 2020, Journal of Immunotherapy for Cancer.

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

R. Herbst, D. Camidge, F. Barlesi, 2021, Annals of Oncology.

Bad Blood: A Case Study of the Tuskegee Syphilis

C. R. Fourtner, R. Herbst, C. F. Herreid, 1994 .

The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer.

R. Herbst, M. O'Reilly, M. O’Reilly, 2003, Seminars in oncology.

Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene

I. Wistuba, R. Herbst, S. Seshagiri, 2005 .

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro).

R. Herbst, S. Novello, G. Ceresoli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma

R. Herbst, W. Novotny, P. O'dwyer, 2008 .

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer

N. Hanna, R. Herbst, F. Shepherd, 2008 .

Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies

S. Lippman, R. Herbst, Y. Oh, 2008 .

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

J. Crowley, R. Herbst, F. Hirsch, 2012, Clinical Cancer Research.

Patient selection criteria and the FLEX Study

R. Herbst, F. Hirsch, 2009, The Lancet.

DesignofaPhaseIIIClinicalTrialwithProspectiveBiomarker Validation: SWOG S0819

J. Crowley, R. Herbst, F. Hirsch, 2012 .

Abstract PO-263: COVID-19 and social determinants of health (SDOH): Impact on cancer prevention in vulnerable populations

R. Herbst, Sakinah C. Suttiratana, S. Alsup, 2020 .

Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.

R. Herbst, J. Soria, M. Hellmann, 2017 .

Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.

R. Herbst, C. Fuchs, J. Bendell, 2017 .

Targeted therapy in non-small-cell lung cancer.

R. Herbst, 2002, Oncology.

Handbook of Advanced Cancer Care: Head and neck cancer

R. Herbst, M. Kies, 2003 .

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of Clinical Oncology.

A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).

C. Obasaju, R. Herbst, K. Pisters, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006

R. Herbst, F. Hirsch, H. Pass, 2007 .

First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors

R. Herbst, E. Rasmussen, R. Kurzrock, 2007 .

Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.

J. Crowley, R. Herbst, K. Kelly, 2005, Clinical lung cancer.

BATTLE (Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination)

Edward S. Kim, R. Herbst, L. Mao, 2008 .

143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

G. Giaccone, R. Herbst, J. Jassem, 2017 .

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

R. Herbst, M. Nishio, M. Reck, 2019, Journal of Clinical Oncology.

A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC

R. Herbst, P. Fidias, D. Prager, 2005 .

S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.

R. Herbst, F. Hirsch, K. Kelly, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303): An interim report of toxicity and response

A. Bleyer, H. Choy, R. Herbst, 2005 .

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy

R. Herbst, C. Stevens, R. Komaki, 2003 .

An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model

Elizabeth B White, M. C. Muenker, S. Farhadian, 2023, Human Genomics.

Personalized therapy.

R. Herbst, P. Ujházy, 2012, Journal of Thoracic Oncology.

Lung Cancer in the Era of Precision Medicine

R. Herbst, K. Politi, 2015, Clinical Cancer Research.

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

R. Herbst, J. Eder, J. Jürgensmeier, 2014, Clinical Cancer Research.

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

R. Herbst, J. Vermorken, N. Amellal, 2008, Cancer.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

C. Obasaju, G. Scagliotti, R. Herbst, 2010, Clinical lung cancer.

Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis

I. Wistuba, R. Herbst, R. Komaki, 2012, Clinical Cancer Research.

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

R. Herbst, J. Nemunaitis, F. Kabbinavar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.

F. Cappuzzo, R. Herbst, T. Mitsudomi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC

R. Herbst, S. Novello, P. Baas, 2021 .

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

R. Herbst, N. Saijo, W. Eberhardt, 2009 .

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

R. Herbst, N. Vasan, J. Boyer, 2014, Clinical Cancer Research.

Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging

R. Herbst, H. Krumholz, M. Joel, 2023, Cancers.

Using Adversarial Images to Assess the Stability of Deep Learning Models Trained on Diagnostic Images in Oncology

J. Duncan, R. Herbst, A. Omuro, 2021 .

“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation

P. Salovey, A. Latimer-Cheung, R. Herbst, 2014, Clinical Cancer Research.

New targets for the treatment of advanced non-small cell lung cancer.

Edward S. Kim, F. Khuri, R. Herbst, 2002 .

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

J. Neal, H. Wakelee, R. Herbst, 2023, Journal of Clinical Oncology.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.

R. Herbst, P. Elvin, A. Platt, 2013 .

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Shing M. Lee, R. Herbst, S. Gettinger, 2023, JCO clinical cancer informatics.

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

R. Herbst, E. Rasmussen, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

A. Bleyer, H. Choy, R. Herbst, 2010, Journal of the National Cancer Institute.

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study.

J. Baselga, R. Herbst, C. Saura, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

Ryan D. Chow, D. Jain, R. Herbst, 2019, Cell systems.

Molecular targeted therapy for lung cancer

R. Herbst, A. Onn, 2005, The Lancet.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

R. Herbst, K. Politi, D. Morgensztern, 2015, JAMA oncology.

Immunotherapeutic Approaches to the Treatment of Squamous Non-Small Cell Lung Cancer

R. Herbst, 2015 .

Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology.

K. Viswanath, R. Herbst, A. Alberg, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.